Share Name Share Symbol Market Type Share ISIN Share Description
Salvarx Grp LSE:SALV London Ordinary Share IM00BZ4SS228 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 40.25p 38.75p 40.00p - - - 25,095 15:00:15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -2.5 -0.1 - 14.68

Salvarx Grp Share Discussion Threads

Showing 101 to 124 of 125 messages
Chat Pages: 5  4  3  2  1
DateSubjectAuthorDiscuss
28/6/2017
18:26
i believe the guinea pig(I mean one patient)isthtit???? size ofplacingis
andymunchkin
23/6/2017
18:24
Okay,186k buy on 21st is some vote of confidence.Fig.
fig1
22/6/2017
13:06
News from last week; Intensity Therapeutics Issued New Patents for Technology Platform US Patent 9,636,406 broadens existing claims for the Company’s proprietary technology Australia intends to grant the Company patent 2013318338 June 15, 2017 07:35 AM Eastern Daylight Time WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States Patent and Trademark Office (PTO) issued the Company patent 9,636,406. In addition, the Company noted that the Australian PTO intends to grant Intensity patent 2013318338. “IntensityR17;s DfuseRxSM platform has identified our lead drug, INT230-6. This novel product, now in clinical trials, has shown great promise in regressing tumors and extending life in animal models of metastatic cancer,” said Intensity’s President and CEO, Lewis H. Bender. “The newly issued U.S. patent and soon-to-be issued Australian patent allow us to protect our unique technology. The Company now has multiple issued patents and several patent applications in the U.S. and countries around the world. U.S. patent 9,636,406 and near-term issuance of Australian patent 2013318338 increases the likelihood that our products can be secured in important markets.”
doodlebug4
22/6/2017
12:32
Mr Mellon sounding very confident about Salva rx htTps://twitter.com/jimmhk/status/877437555200987136
the stigologist
22/6/2017
10:23
Also I think FFWD had RNS on Intensity couple of days ago but SALV didn't
the stigologist
22/6/2017
10:20
i believe the guinea pig(I mean one patient) that is receiving the Intensity Therapeutics treatment is not only still alive but the tumour has markedly reduced. Hold the front page!
wiseacre
21/6/2017
16:24
Funny said that on lse
korvet
21/6/2017
15:46
Boooooooommm!!!!
joemillion
21/6/2017
14:38
Wow. Does nothing for ever, now this in days, all on "no news".
spectoacc
21/6/2017
13:22
Close to a breakout. Wonder if there is any news imminent?
the stigologist
20/6/2017
16:56
Something is up. It is unusual for the share price to move this much. I suspect that some people know something that I don't. should be positive.
kingston78
20/6/2017
08:15
Seen no news but seeing some keen buyers & small free float makes it very interesting.
spectoacc
19/6/2017
22:36
Certainly does. Up over 9% today on five small buys. Only a matter of time before it really takes over.
joemillion
08/6/2017
14:05
Does anyone have any news about this company? The share price sometimes move by quite a bit without any apparent reason?
kingston78
30/5/2017
14:42
Some more details about the trials from www.clinicaltrials.gov https://www.clinicaltrials.gov/ct2/show/NCT03058289?term=NCT03058289&rank=1
doodlebug4
30/5/2017
13:26
Finally some news - hopefully soon going to get very interesting!
spectoacc
06/4/2017
14:53
Great news today.Anyone selling HAS to sell for whatever reason.Fig.
fig1
06/4/2017
12:03
WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary immune cell-activating cancer treatments, announced that tumor regression and immune activation data generated by the Company’s lead drug, INT230-6, will be presented in a poster session at the American Academy of Cancer Research (AACR) meeting on April 5, 2017. The research being presented indicates that INT230-6 results in complete response of tumors in rodent models, induces protective T cell immunity and is synergistic with checkpoint inhibitors. Dr. Anja Bloom from the Vaccine Branch of the National Cancer Institute (NCI) and Lewis H. Bender, CEO of Intensity Therapeutics will present the poster presentation.
the stigologist
06/4/2017
11:37
We should back this company. The amount of investment depends on your risk appetite. We may hit the jackpot one day.
kingston78
06/4/2017
11:32
http://www.businesswire.com/news/home/20170404005049/en/Intensity-Therapeutics-Reports-INT230-6-Induces-Protective-T-Cell
fig1
27/3/2017
22:16
www.proactiveinvestors.co.uk/columns/northland-capital-partners-view-on-the-city/27337/northland-capital-partners-view-on-the-city-immupharma-plc-salvarx SalvaRx (LON:SALV) – BUY*: New investment Market Cap: £11m; Current Price: 29p; Target Price: 149p Investment in Rift Biotherapeutics Inc. SalvaRx announced that it has entered into an agreement to invest in Rift Biotherapeutics Inc. (Rift), a private, Delaware-domiciled biotechnology company focused on the development of antibodies for use in oncology. Under the terms of the agreement, SalvaRx will invest US$1,000,000 for an initial holding of approximately 30% (including new shares issued on the conversion of a US$90,000 convertible loan already provided to Rift) in the company. Subject to Rift achieving certain development milestones with this initial funding, SalvaRx has the option to invest up to an additional US$1,500,000 at the same valuation and to acquire all outstanding shares of Rift in exchange for new shares in SalvaRx on the same basis. The initial investment has been funded from existing cash resources. Rift, an early stage research and development company, was founded in 2015 in order to discover and develop first-in-class antibodies implicated in the inflammatory tumour and tumour infiltrating immune cells microenvironment. NORTHLAND CAPITAL PARTNERS VIEW: SalvaRx continues delivering on its expansion strategy of building a broad portfolio of immune-oncology assets. Rift represents SalvaRx’s fourth immune-oncology portfolio company. The group has discovered several candidate antibodies to novel immune check point targets. The group’s novel non T-cell based immunotherapy targets offer complementary approaches to the current standard of care in this area. The market for immuno-oncology products is forecast to expand to $80bn by 2020.
the stigologist
27/3/2017
09:27
Agreed, with the added kicker of a restricted free float - if there is reason for it to fly, it should really go for it.
spectoacc
27/3/2017
09:21
Patience is the virtue in this sort of investment. One may hit the jackpot one day. Good luck.
kingston78
27/3/2017
08:03
Thanks, seems to have caused a few buys first thing in a negative market.
spectoacc
Chat Pages: 5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20170720 14:45:21